Merck & Co., Inc. is a global healthcare company that develops and markets prescription medicines, including biologic therapies and vaccines, for human health, and a wide range of veterinary pharmaceuticals, vaccines, and health management solutions for animal health. The company's main products include oncology treatments like Keytruda, various vaccines such as Gardasil, and animal health products like Bravecto.
Wall Street consensus — sourced weekly via public disclosures
Analyst coverage data sourced from public filings. Xavier analyst thesis summary available after weekly Perplexity scan completes.
Financial summary — Gemini analysis
Signal
Revenue
$65,011 million
1% YoY
Operating margin
32.4%
Net income
$18,254 million
Free cash flow
$12,360 million
Dividend / share
$3.28
Total debt
$49,339 million
Cash: $14,565 million
CapEx guidance
$20 billion from 2025-2029
Earnings quality:MEDIUM
Recurring revenue:99%
Cash conversion:0.9x
Non-recurring items: Acquisition- and divestiture-related costs of $3,007 million, Restructuring costs of $2,551 million, Net gain from investments in equity securities of $306 million, Net tax benefit related to favorable audit reserve adjustments of $60 million
Confidence 6.2 / 10 · 100% model agreement ·
Scheduled Jun 07, 2026
MRK trades at a TTM P/E of 34x — well above the pharma sector average — with revenue growth nearly flat (0.049%) and a Q1 2026 EPS print distorted by a ~$3.62/share acquisition charge tied to Cidara Therapeutics. The forward P/E of ~12.6x implies the market is discounting meaningful earnings normalization, likely reflecting the looming Keytruda patent cliff in 2028 and IRA Medicare pricing pressure on its flagship asset, which represents roughly 40% of pharma revenues. While Keytruda Q1 2026 sales of $8.03B grew 12% YoY and Winrevair is ramping strongly, the absence of near-term catalysts within a 5-day window, a neutral-to-bearish macro regime, stretched TTM valuation, and a stock sitting just 3% below its 52-week high limit incremental upside.
Strongest bull case
Forward P/E of ~12.6x is deeply discounted relative to the TTM multiple, implying the market has already priced in significant Keytruda patent cliff risk — if pipeline assets (Winrevair +88% YoY, calderasib Breakthrough Therapy designation, mRNA cancer vaccine with Moderna) outperform, re-rating is possible well before 2028.
Strongest bear case
Keytruda accounts for an estimated 40% of Merck's pharmaceutical revenues and faces core U.S. patent expiry in 2028, putting over $25B in annual revenue at biosimilar risk; combined with IRA Medicare pricing pressure already flowing through and Gardasil sales down 19% YoY in Q1 2026, top-line re-acceleration is structurally constrained in the near term with no identifiable 5-day catalyst to reprice the stock higher.
What the market may be missing
The subcutaneous Keytruda formulation (Keytruda SC/Qlex), which posted $128M in its very first quarter and carries its own new patent estate potentially extending exclusivity to 2036, may be materially undervalued as a lifecycle management hedge — if uptake accelerates and payers accept it as non-interchangeable with the IV formulation, biosimilar erosion post-2028 could be far shallower than current consensus assumes.
Chairman, Chief Executive Officer, and President · Merck & Co. Inc.
CEO since 2021
Total compensation
$20,797,845 ▼ 10.3% YoY
Prior year: $23,186,064
Pay vs performance
Aligned
Board assessment
Say-on-pay approval
91%
Shareholder vote
Board independence
12/13 (92%)
Base salary$1,650,000
Bonus / incentive$2,326,500
Stock awards$12,102,838
Executive appearances
Intel
Free
Industry Event2025-12-00
White House Press Conference with Pharmaceutical Leaders Source ↗
Mr. Robert M. Davis J.D. (CEO) · White House
Robert M. Davis stood with other pharma CEOs behind President Trump, declaring full support for the president's actions on drug pricing. He addressed high prices for Keytruda, starting at $24,000 per dose and often increasing, while vowing Merck woul
“"100% support for the president’s actions and vowed Merck would drop prices on a diabetes drug and a cardiovascular pill."”
Investor Day2026-02-00
Merck 2025 Full Year and Q4 Earnings Call Source ↗
Mr. Robert M. Davis J.D. (CEO) · Merck & Co.
In the earnings call, executives including Davis touted recent deals and Merck's strengthened position as a research-driven innovator in oncology, vaccines, and new therapies for cardiometabolic, respiratory, and infectious diseases. Emphasis was pla
Industry EventDec 20, 2025
White House Pharmaceutical Companies Meeting Source ↗
Mr. Robert M. Davis J.D. (CEO) · Roosevelt Room, White House
Merck CEO Robert M. Davis joined leaders of nine pharmaceutical companies in a meeting with President Donald Trump just days before Christmas 2025. Davis promoted industry agendas including strong patent protection and high drug prices to recover R&D
“"Patent protection and high prices help drug companies recover the billions spent developing new medicines and getting them to patients safely on a mass scale."”
CEO letter to shareholders
Signal
No shareholder letter on file for MRK
Some companies file their annual report without a separate CEO letter.
When available, Xavier extracts strategic themes, tone analysis, and
forward-looking statements to help you read between the lines.
Executive compensation
Signal
Name
Title
Total compensation
Robert M. Davis
Chairman, Chief Executive Officer, and President
$20,797,845
Caroline Litchfield
Executive Vice President and Chief Financial Officer
$7,514,085
Sanat Chattopadhyay
Executive Vice President and President, Merck Manufacturing Division
$5,408,408
Dean Li, M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
$8,892,881
Jennifer Zachary
Executive Vice President and General Counsel
$5,860,578
Source: DEF 14A proxy statement · 2026-04-08
Governance
Pro
Dual-class shares:No
Poison pill:No
Clawback policy:Yes
Stock ownership req.:Yes
Shareholder proposals
Report on DEI Risks In Federal Contracting
AGAINST
Pending
Report on Healthcare Coverage Gaps
AGAINST
Pending
Report on Political Contributions
AGAINST
Pending
Debt intelligence
Pro
1.07x
Debt / Equity
7.6x
Interest coverage
3.0x
Net Debt / EBITDA
$43.8B
Net debt
38%
Debt / Assets
Xavier risk radar
Pro
Covenant headroom
Moderate leverage — no covenants on file
Earnings quality
MEDIUM (cash conversion 0.9x)
Risk trend
Risk increasing — The Company is dependent on its patent rights, and if its patent rights are inva
Mgmt narrative
Management tone: Cautiously optimistic
Analyst drift
Consensus Buy — targets stable
Insider sentiment
Pattern detection — 90 days needed
Signal history
Signal
Date
Direction
Conf.
Agree.
Thesis
Price
Type
Jun 07, 2026
NEUTRAL
6.2/10
100%
MRK trades at a TTM P/E of 34x — well above the pharma sector average — with revenue growth nearly f...
$120.79
Sched.
May 31, 2026
NEUTRAL
6.0/10
75%
MRK has rallied ~57% off its 52-week low on pipeline optimism (Sac-TMT OS/PFS beats, calderasib Brea...
$118.72
Sched.
May 24, 2026
NEUTRAL
6.3/10
75%
MRK has surged ~5.7% in a single session on a wave of genuine pipeline catalysts — EU CHMP positive ...
$122.41
Sched.
May 17, 2026
NEUTRAL
5.6/10
100%
MRK trades at 31x TTM P/E — elevated for a company with near-zero revenue growth (~1.3% in FY2025) a...
$111.38
Sched.
May 10, 2026
NEUTRAL
6.6/10
100%
MRK has supportive macro tailwinds as a low-beta defensive pharma name and still trades well below a...
$111.38
Sched.
May 03, 2026
BULLISH
7.0/10
75%
MRK just delivered a clean Q1 2026 earnings beat — revenue of $16.29B vs. $15.82B est., adj. EPS bea...
$112.16
Sched.
Apr 12, 2026
BULLISH
6.9/10
75%
MRK trades at a forward P/E of ~12.4x — a meaningful discount to both industry peers and its own 5-y...
$121.42
Sched.
Showing last 7 signals
MRKMerck & Co. Inc.
Signal
FY2026 annual report (10-K filed 2026-02-24)
INCOME STATEMENT
?Revenue
$65,011 million1% YoY
Total sales from drugs, medical devices, insurance premiums, and healthcare services. Up 1% from last year. Management has guided capital spending of $20 billion from 2025-2029.
?Operating income
$21,067 million
What remains after subtracting all operating costs — salaries, materials, rent, R&D — from revenue. This is the profit from actually running the business, before interest and taxes. Operating margin is 32.4%, meaning 32 cents of every dollar of revenue becomes operating profit.
?Net income
$18,254 million
The bottom line — what the company actually earned after all expenses, interest, and taxes. This is the number that gets divided by shares outstanding to calculate earnings per share (EPS), which directly affects the stock price. Net margin is -26.0%. Note: results include non-recurring items (acquisition- and divestiture-related costs of $3,007 million, restructuring costs of $2,551 million) that may not repeat.
?Free cash flow
$12,360 million
Operating cash flow minus capital expenditure. This is the money available for dividends, share buybacks, debt repayment, or acquisitions. Free cash flow is what many professional investors consider the truest measure of financial health.
?EPS (diluted)
$-1.72
Earnings per share — net income divided by total shares outstanding (including stock options and convertible bonds that could become shares). This is the single number most investors watch because it directly connects company profits to your ownership stake.
?Dividend per share
$3.28
Cash paid to shareholders each year for every share they own. Healthcare dividends are often funded by patent-protected drug revenue with predictable cash flows.
BALANCE SHEET
?Total assets
$128.7B
Everything the company owns — cash, factories, equipment, patents, inventory, investments. Includes drug patents, manufacturing facilities, clinical trial data, and acquired pharmaceutical portfolios.
?Cash & equivalents
$14,565 million
Money available right now — bank accounts, money market funds, short-term government bonds. This is the company's financial cushion. More cash means more flexibility to invest, acquire, or survive a downturn without borrowing.
?Total debt
$49,339 million
All money the company owes — bonds, bank loans, credit facilities. Compare this to cash to understand the net debt position. The company holds $14,565 million in cash against this debt.
?Shares outstanding
2,472,392,003 shares
Total number of shares that exist — owned by all investors, insiders, and institutions combined. When the company reports EPS, this is the denominator. Share buybacks reduce this number, which increases EPS even without earnings growth.
?Debt-to-equity ratio
1.0%
How much debt the company uses for every dollar of shareholder equity. Under 100% means more equity than debt (conservative). Over 200% means heavy leverage. Banks and utilities naturally run higher ratios.
CASH FLOW
?Operating cash flow
$3.9B
Actual cash generated from running the business — not accounting profits, real money coming in the door. This is more trustworthy than net income because it's harder to manipulate. A company can report profits but still run out of cash.
?Capital expenditure
$991M
Money spent on long-term assets — manufacturing plants, research labs, and clinical trial infrastructure. This is the cost of maintaining and growing the business. Management has guided $20 billion from 2025-2029 for capital spending.
?Free cash flow
$2.9B
Operating cash flow minus capital expenditure. This is the money available for dividends, share buybacks, debt repayment, or acquisitions. Free cash flow is what many professional investors consider the truest measure of a company's financial health.
?Depreciation & amortization
$581M
A non-cash expense that spreads the cost of pharmaceutical manufacturing equipment and acquired drug patents over their useful life. This reduces reported income but no cash actually leaves the company — that's why it gets added back to calculate EBITDA and operating cash flow.
EARNINGS QUALITY
?Accrual quality
MEDIUM
Measures how well reported earnings match actual cash generation. HIGH means earnings are backed by real cash. LOW means the company may be using accounting techniques to inflate reported numbers. Professional investors check this before trusting EPS.
?Recurring revenue
99%
99% of revenue comes from repeat sources — ongoing contracts, subscriptions, or regular customer purchasing patterns rather than one-time sales. Higher recurring revenue means more predictable future earnings.
?Cash conversion
0.9x
Operating cash flow divided by net income. Above 1.0x means the company generates more cash than it reports in profits — a sign of high-quality earnings. At 0.9x, the company is generating less cash than reported profits — investigate why.
?Non-recurring items
8 identified
One-time items that affect the bottom line but won't repeat: acquisition- and divestiture-related costs of $3,007 million, restructuring costs of $2,551 million, net gain from investments in equity securities of $306 million, net tax benefit related to favorable audit reserve adjustments of $60 million. When evaluating the company's true earning power, investors strip these out to see what the business earns on a normal basis.
?Management tone
Cautious Optimistic
How management sounds in their SEC filings — are they confident, cautious, or defensive? This is analyzed from the actual language used in the 10-K annual report. A shift in tone from prior years can signal changing conditions before the numbers reflect it.
?Top risk factor
Increasing
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected. Risk trend: increasing. This is the single biggest threat to the company's future earnings as identified in their SEC filing.
Click any row to expand the plain-English explanation. Source: SEC EDGAR XBRL filings.
Capital intelligence
Signal
Weighted Average Cost of Capital · Return on Invested Capital · Economic Value Added
ROIC
10.53%
WACC
5.24%
🟢 VALUE CREATOR — EVA Spread: 5.30%
?WACC
5.24%
Weighted Average Cost of Capital — the minimum return Merck & Co. Inc. must earn on its investments to satisfy both debt holders and shareholders. Computed from a 86.47% equity / 13.53% debt capital structure. If the company earns less than 5.24% on its invested capital, it is destroying shareholder value.
?Cost of equity
5.38%
The return shareholders demand for holding MRK stock instead of a risk-free Treasury bond. Computed using the Capital Asset Pricing Model: Risk-Free Rate (4.25%) + Beta (0.20) × Equity Risk Premium (5.50%). A beta of 0.20 means MRK is less volatile than the overall market.
?Cost of debt (after-tax)
4.35%
What Merck & Co. Inc. effectively pays on its borrowed money after the tax deduction on interest. Interest is tax-deductible, so the true cost is lower than the stated rate. Effective tax rate used: 21.00%.
?Capital structure
E: 86.47% / D: 13.53%
How Merck & Co. Inc. finances its operations — the split between equity (stock market value: $298.3B) and debt (total borrowings: $46.7B). More debt means more leverage — higher potential returns but higher risk.
?ROIC
10.53%
Return on Invested Capital — how efficiently Merck & Co. Inc. turns its total invested capital into after-tax operating profit. NOPAT ($9.2B) ÷ Invested Capital ($87.2B). This exceeds WACC, meaning the company creates value for shareholders.
?EVA
$4.6B
Economic Value Added — the dollar amount of value Merck & Co. Inc. created (or destroyed) above its cost of capital. NOPAT ($9.2B) minus the capital charge (Invested Capital × WACC = $4.6B). Positive EVA means every dollar of capital is earning more than it costs.
?NOPAT
$9.2B
Net Operating Profit After Tax — operating income adjusted for taxes, ignoring how the company is financed. Operating Income ($11.6B) × (1 - Tax Rate 21.00%). This isolates the company's core business profitability from its financing decisions.
Xavier consensus signals are intelligence outputs, not investment advice. All signals are generated by a multi-model AI system and reflect public information at time of generation. Past signal accuracy does not guarantee future performance. Wall Street analyst consensus sourced from public disclosures, summarized weekly. Financial data sourced from SEC EDGAR and yfinance. Insider transactions sourced from SEC EDGAR Form 4 filings. Updated Jun 07, 2026.